Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12135857 | 0.86 | RAPGEF4 (0.44) | RAPGEF4SLC6A3ALDH1A1POLBGAA | |
| SCHEMBL20620249 | 0.84 | RAPGEF4 (0.49) | RAPGEF4ACLY | |
| SCHEMBL21571898 | 0.83 | EGFR (0.40) | RAPGEF4ALDH1A1 | |
| SCHEMBL12203150 | 0.80 | SMN1; SMN2 (0.32) | IDO1 | |
| SCHEMBL12403860 | 0.77 | RAPGEF4 (0.42) | RAPGEF4 | |
| SCHEMBL9905241 | 0.77 | GAA (0.53) | RAPGEF4ALDH1A1POLBGAANPSR1 | |
| SCHEMBL25251371 | 0.75 | RAPGEF4 (0.34) | RAPGEF4SLC6A3 | |
| SCHEMBL8237552 | 0.75 | PIK3CA (0.35) | ALDH1A1POLBGAANPSR1PLK4 | |
| SCHEMBL1011188 | 0.74 | ALDH1A1 (0.44) | ALDH1A1POLBGAA | |
| SCHEMBL19194707 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689331-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-23 | — | — | US | disclosed |
| US-10479793-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-11-19 | — | — | US | disclosed |
| US-20190002402-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-03 | — | — | US | disclosed |
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-17 | — | — | US | disclosed |
| US-7846931-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| WO-2007045861-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479793-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | TYK2, IL2, JAK3 | RAPGEF4 3690/4885SLC6A3 3796/4885ALDH1A1 3639/4885 |
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | RAPGEF4 677/4885SLC6A3 3581/4885ALDH1A1 3252/4885 |
| US-20190002402-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | RAPGEF4 4382/4885SLC6A3 2394/4885ALDH1A1 707/4885 |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | RAPGEF4 677/4885SLC6A3 3581/4885ALDH1A1 3252/4885 |
| US-10689331-B2 | IDO inhibitors | IDO1, IDO2, INMT | RAPGEF4 4382/4885SLC6A3 2394/4885ALDH1A1 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.